Skip to content

Trial Summary

The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.



ACTRN/NCT /ethics:


Scientific title:

A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line PlatinumContaining Chemotherapy

Sponsor / Cooperative group:

EMD Serono Research & Development Institute, Inc.

Trial & Patient Characteristics

Cancer TypeBladder
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream Urothelial
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2022-08-17
Anticipated End Date2026-08-05

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting